DBV Technologies price target raised to $15 from $10 at Citizens JMP

Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on DBV Technologies (DBVT) to $15 from $10 and keeps an Outperform rating on the shares. DBV’s $128M in pro forma cash provides runway into the second quarter of 2026 before considering the potential $180M from warrants that would be exercised on success in the Phase 3 VITESSE trial in the fourth quarter of 2025, the analyst tells investors in a research note. DBV has strung together multiple positive developments this year, including three-year data in 1-3 year olds, showing Viaskin Peanut’s safety and efficacy improve over time, and management just needed to shore up the balance sheet, the firm says.